Viracta Therapeutics (NASDAQ:VIRX) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.
Valuation and Earnings
This table compares Viracta Therapeutics and Evaxion Biotech A/S's gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
|---|
| Viracta Therapeutics | N/A | N/A | N/A | N/A | N/A |
| Evaxion Biotech A/S | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares Viracta Therapeutics and Evaxion Biotech A/S's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
|---|
| Viracta Therapeutics | N/A | N/A | N/A |
| Evaxion Biotech A/S | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of recent recommendations for Viracta Therapeutics and Evaxion Biotech A/S, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
|---|
| Viracta Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
| Evaxion Biotech A/S | 0 | 0 | 2 | 0 | 3.00 |
Viracta Therapeutics currently has a consensus price target of $33.50, suggesting a potential upside of 336.20%. Evaxion Biotech A/S has a consensus price target of $18.00, suggesting a potential upside of 221.43%. Given Viracta Therapeutics' higher probable upside, equities research analysts clearly believe Viracta Therapeutics is more favorable than Evaxion Biotech A/S.
Summary
Viracta Therapeutics beats Evaxion Biotech A/S on 2 of the 2 factors compared between the two stocks.
